J 2024

Aronia melanocarpa L. fruit peels show anti-cancer effects in preclinical models of breast carcinoma: The perspectives in the chemoprevention and therapy modulation

DVORSKA, Dana; Alena MAZURAKOVA; Lenka LACKOVA; Dominika SEBOVA; Karol KAJO et. al.

Základní údaje

Originální název

Aronia melanocarpa L. fruit peels show anti-cancer effects in preclinical models of breast carcinoma: The perspectives in the chemoprevention and therapy modulation

Autoři

DVORSKA, Dana (703 Slovensko); Alena MAZURAKOVA (703 Slovensko); Lenka LACKOVA (703 Slovensko); Dominika SEBOVA (703 Slovensko); Karol KAJO (703 Slovensko); Marek SAMEC (703 Slovensko); Dusan BRANY (703 Slovensko); Emil ŠVAJDLENKA (203 Česká republika, domácí); Jakub TREML (203 Česká republika, domácí); Sandra MERSAKOVA (703 Slovensko); Jan STRNADEL (703 Slovensko); Marian ADAMKOV (703 Slovensko); Zora LASABOVA (703 Slovensko); Kamil BIRINGER (703 Slovensko); Jan MOJZIS (703 Slovensko); Dietrich BUSSELBERG (634 Katar); Karel ŠMEJKAL (203 Česká republika, domácí); Martin KELLO (703 Slovensko) a Peter KUBATKA (703 Slovensko)

Vydání

Frontiers in Oncology, Lausanne, FRONTIERS MEDIA SA, 2024, 2234-943X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.500 v roce 2023

Kód RIV

RIV/00216224:14160/24:00139007

Organizační jednotka

Farmaceutická fakulta

UT WoS

001339459500001

EID Scopus

2-s2.0-85207005369

Klíčová slova anglicky

Aronia melanocarpa L.; rodent models; breast carcinoma; in vitro models; mechanism of action; epigenetics

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 6. 3. 2025 07:10, Mgr. Daniela Černá

Anotace

V originále

Introduction Within oncology research, there is a high effort for new approaches to prevent and treat cancer as a life-threatening disease. Specific plant species that adapt to harsh conditions may possess unique properties that may be utilized in the management of cancer. Hypothesis Chokeberry fruit is rich in secondary metabolites with anti-cancer activities potentially useful in cancer prevention and treatment. Aims of the study and Methods Based on mentioned hypothesis, the main goal of our study was to evaluate the antitumor effects of dietary administered Aronia melanocarpa L. fruit peels (in two concentrations of 0.3 and 3% [w/w]) in the therapeutic syngeneic 4T1 mouse adenocarcinoma model, the chemopreventive model of chemically induced mammary carcinogenesis in rats, a cell antioxidant assay, and robust in vitro analyses using MCF-7 and MDA-MB-231 cancer cells. Results The dominant metabolites in the A. melanocarpa fruit peel extract tested were phenolic derivatives classified as anthocyanins and procyanidins. In a therapeutic model, aronia significantly reduced the volume of 4T1 tumors at both higher and lower doses. In the same tumors, we noted a significant dose-dependent decrease in the mitotic activity index compared to the control. In the chemopreventive model, the expression of Bax was significantly increased by aronia at both doses. Additionally, aronia decreased Bcl-2 and VEGF levels, increasing the Bax/Bcl-2 ratio compared to the control group. The cytoplasmic expression of caspase-3 was significantly enhanced when aronia was administered at a higher dosage, in contrast to both the control group and the aronia group treated with a lower dosage. Furthermore, the higher dosage of aronia exhibited a significant reduction in the expression of the tumor stem cell marker CD133 compared to the control group. In addition, the examination of aronia`s epigenetic impact on tumor tissue through in vivo analyses revealed significant alterations in histone chemical modifications, specifically H3K4m3 and H3K9m3, miRNAs expression (miR155, miR210, and miR34a) and methylation status of tumor suppressor genes (PTEN and TIMP3). In vitro studies utilizing a methanolic extract of A.melanocarpa demonstrated significant anti-cancer properties in the MCF-7 and MDA-MB-231 cell lines. Various analyses, including Resazurin, cell cycle, annexin V/PI, caspase-3/7, Bcl-2, PARP, and mitochondrial membrane potential, were conducted in this regard. Additionally, the aronia extract enhanced the responsiveness to epirubicin in both cancer cell lines. Conclusion This study is the first to analyze the antitumor effect of A. melanocarpa in selected models of experimental breast carcinoma in vivo and in vitro. The utilization of the antitumor effects of aronia in clinical practice is still minimal and requires precise and long-term clinical evaluations. Individualized cancer-type profiling and patient stratification are crucial for effectively implementing plant nutraceuticals within targeted anti-cancer strategies in clinical oncology.